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Background: The worldwide incidence of gastric cancer (GC) has been increasing in
young patients (YP) over the past few decades. It is unclear whether there are differen-
ces in disease characteristics and prognosis between YP and older patients (OP). This
review examines the differences in presentation and outcomes between YP and OP.
Methods: A retrospective review of all cases of sporadic GC referred to the Kuwait
Cancer Control Center (KCCC) between 2008 and 2016 was conducted. We collected
data on patients’ demographics, risk factors, disease clinicopathologic characteristics,
stage at diagnosis and survival. Patients at the age of 50 years or younger at the time of
diagnosis were designated as YP. Continuous variables were summarized with mean
and standard deviation, or median and interquartile range (IQR) as appropriate and
compared withMann-Whitney U test. Categorical variables were described as frequen-
cies (percent) and compared with Fisher’s exact test. A level of 0.05 was defined as stat-
istically significant.
Results: Evaluable data were available for 167 patients. 52 (31.1%) where YP. Themean
age was 43.2 (65.7) years for YP compared with 64.3 (68.4) years for OP. In YP 63.5%
were males compared to 72.2% in EG, p¼ 0.28. YP tends to present more with epigas-
tric pain as opposed to OP who presented with GI bleed (hematemesis, melena or
symptomatic anemia). There were less smokers in YP (23.1%) relative to OP (42.5%),
p¼ 0.009. We found no difference with regards to family history, H. Pylori status, his-
tological subtype, grade or stage at diagnosis. The overall survival was 78.8% for YP ver-
sus 63.5% for OP, p¼ 0.051.
Conclusions: Compared to their older counter parts, YP with GC tend to present with
more epigastric pain and less likely to be smokers. No significant differences were found
in disease characteristics or outcomes between YP and OP.More research is needed to
further understand the raise of GC among YP.
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Background: POCOP is a novel prospective scientific database including oesophago-
gastric cancer patients, initiated by the Dutch Upper GI Cancer Group (DUCG) to
stimulate multidisciplinary research. Within POCOP treatment and diagnostic strat-
egies as well as prognostic and predictive factors for outcome can be evaluated on a
population-based level. We present the design and current proceedings.
Methods: All patients with oesophagogastric cancer in the Netherlands are eligible.
Patients need to provide consent for: 1) the reuse of clinical data collected by the
Netherlands Cancer Registry (NCR), 2) longitudinal collection of patient reported
outcomes (PROs), receiving future information on new interventional studies (includ-
ing cohort multiple randomized controlled trials (cmRCT)), and/or 3) linkage with
Dutch databases e.g. the Dutch Upper GI Cancer Audit, the biobank of The Parelsnoer
Institute and general practitioner databases. Funding: Dutch Cancer Society (UVA
2014-7000).
Results: Thus far, clinical data is being collected from almost all Dutch patients with
oesophagogastric cancer diagnosed from 2015 onwards. Clinical data mainly consist of
patient, tumour andmultidisciplinary sequential treatment characteristics. The collec-
tion of longitudinal PROs started in 2016. Of all patients who gave consent (N¼ 1000),
92% also participated in the PRO-registry. PRO compliance was 87%, 67% and 46%
(not accounted for death or drop-out) at diagnosis, 3 and 6months follow-up, respec-
tively. 81% of patients consented to receive future information on new interventional
studies, including cmRCTs. Collaborations with phase II/III trials and other cohort
studies were established to reduce patient burden regarding completion of PROs and
trial registration burden. Obtained data is governed by the DUCG scientific committee
which includes members of participating hospitals, the study team and the NCR.
Conclusions: POCOP provides real world population-based data to stimulate (inter-
)national multidisciplinary research and provides the opportunity to perform novel tri-
als within the established infrastructure. Researchers can acquire data by submitting a
research proposal to the scientific committee of the DUCG (www.ducg.nl).
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Background: Codrituzumab (Cod) is a recombinant humanized monoclonal antibody
against Glypican-3 (GPC3). GPC3 is over-expressed in hepatocellular carcinoma
(HCC). Cod elicits antibody-dependent cellular cytotoxicity against human HCC cell
lines and shows more potent anti-tumor activity when combined with anti-PD-L1 anti-
body in syngeneic mouse model. This is a phase I dose-escalation study to evaluate
safety/tolerability and pharmacokinetics in combination with the anti-PD-L1 antibody,
atezolizumab (Atezo) in advanced HCC patients.
Methods: This study is composed of a 3þ 3 dose-escalation part and an expansion
part. Patients with advanced or metastatic HCCwho had failed prior systemic therapy,
GPC3 high expression, ECOG PS 0-1, Child-Pugh A-B7 were eligible. Cod given intra-
venously 800 or 1600mg on Day 1, 4, then weekly fromDay 8 combined with 1200mg
every 3 weeks dosing of Atezo until disease progression/toxicity. The objectives were to
determineMTD of Cod and Atezo combination primarily, to assess safety, antitumor
effect (RECIST 1.1) and pharmacokinetics secondarily, and to assess biomarkers
exploratory.
Results: Ten patients each were enrolled in dose-escalation and expansion parts,
respectively. There were 16men/4 women, median age 58, all Asian, HBV/HCV/neither
11/4/5, ECOG 0/1 15/5. No dose limiting toxicities were observed in dose-escalation
part. The most frequently observed adverse events (AEs) were pyrexia (80%), fatigue
(50%), decreased appetite (30%), aspartate aminotransferase increased, lymphocyte
count decreased (25%), constipation, cough, nasopharyngitis (20%). Grade 3 or higher
AEs ( 2 patients) were aspartate aminotransferase increased, lymphocyte count
decreased (20%), anemia (15%), and ascites (10%). There was 1 confirmed PR, 10 SD
(including 1 unconfirmed PR) among 18 evaluable patients and 6 of them had SD for
more than 6months before progression.
Conclusions: Codþ Atezo combination was well-tolerated and showed antitumor
activity in this advanced, previously treated and GPC3 highly expressed HCC patients.
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